Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Sweden
/
Pharmaceuticals & Biotech
/
Oncopeptides
ONCO
Oncopeptides
Oncolytics Biotech: A Beacon of Hope in Cancer Treatment
DA
DailyInvestors
Invested
Community Contributor
Published
24 Feb 25
Updated
24 Feb 25
4
Set Fair Value
0
votes
1
Share
DailyInvestors
's Fair Value
SEK 2.56
63.5% overvalued
intrinsic discount
24 Feb
SEK 4.19
Loading
1Y
90.2%
7D
-10.0%
Author's Valuation
SEK 2.6
63.5% overvalued
intrinsic discount
DailyInvestors's Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
DailyInvestors
's
Fair Value
SEK 2.6
63.5% overvalued
intrinsic discount
Future estimation in
5 Years
time period
Past
Future
-2b
503m
2014
2017
2020
2023
2025
2026
2029
2030
Revenue SEK 502.6m
Earnings SEK 100.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
61.90%
Biotech revenue growth rate
11.97%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
4.92%
Calculation
SEK 100.11m
Earnings '30
x
27.43x
PE Ratio '30
=
SEK 2.75b
Market Cap '30
SEK 2.75b
Market Cap '30
/
798.97m
No. shares '30
=
SEK 3.44
Share Price '30
SEK 3.44
Share Price '30
Discounted to 2025 @ 6.07% p.a.
=
SEK 2.56
Fair Value '25
